An equal number of sex-, age-, site of onset-, disease-duration-matched untreated patients with ALS were analysed as a control group
Disclaimer: This product is not intended to diagnose, treat, cure, or prevent any disease
Single dose pens are available via cash pay and are eligible for insurance coverage
Adapted from the Society of Clinical Research Associates 2 Impact of Usability Issues on Clinical Trial Data Conducting HF validation tests before major clinical trials, as recommended by the FDA, supports more reliable trial outcomes by identifying usability issues early in development
(2022b), where a reaction solution with a total volume of 2.1 ml consisted of 0.1 ml 0.06% H 2 O 2 , 1.7 ml of 50 mmol/L potassium phosphate buffer containing 0.1 mmol/L EDTA-Na 2 , 0.1 ml of 6 mmol/L ASC, and 0.1 ml supernatant